atorvastatin

P=N/A, N=2000, Not yet recruiting, Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

P1/2, N=46, Not yet recruiting, Assiut University

P4, N=119, Completed, University of Kansas Medical Center | Active, not recruiting --> Completed

P4, N=240, Active, not recruiting, Chiayi Christian Hospital | Recruiting --> Active, not recruiting

P=N/A, N=300, Active, not recruiting, Assiut University

P=N/A, N=1092, Not yet recruiting, Dalian Municipal Central Hospital; Dalian Municipal Central Hospital

P=N/A, N=302, Not yet recruiting, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University; The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University

P=N/A, N=100, Completed, Riphah International University

A 65-year-old woman with a past medical history of hyperlipidemia on atorvastatin for four years, type 2 diabetes, sciatica, and a prior history of endometrial cancer, presented to the emergency department due to proximal muscle weakness worsening over 2-3 months...During her hospital course, she was started on prednisone, fluids, and intravenous immunoglobulin (IVIG). Once completing two days of IVIG, the patient was discharged to rehab with rheumatology follow-up. The purpose of this case is to elucidate a rare side effect of a medication despite being on it for several years and to increase awareness and attention to an adverse effect that may one day lead to stratifying patients' risk on the medication.

P1/2, N=22, Enrolling by invitation, Johns Hopkins University | Not yet recruiting --> Enrolling by invitation

Atorvastatin, dexamethasone, and PGE2 differentially modulated these inflammatory changes. ACO/eCOPD is associated with viral infection and an inflammatory milieu. Therapeutic strategies using statins and inhaled corticosteroids are recommended to control these pathogenic changes.

P1/2, N=80, Active, not recruiting, University of Chicago | Trial completion date: Jun 2025 --> Mar 2025

Thus, our study presents PUMP as a novel and promising bioactive vesicular nanosystem with potential synergistic effect with ATV or other antitumor drugs. PUMP-integrated MN could be considered a promising platform for future applications in localized breast cancer therapy.

P1/2, N=80, Active, not recruiting, University of Chicago | Trial primary completion date: Dec 2024 --> Jul 2024

P2, N=150, Recruiting, OHSU Knight Cancer Institute | Trial completion date: Mar 2029 --> Sep 2029

P4, N=76, Not yet recruiting, Ohio State University

P2, N=38, Recruiting, Peking University People's Hospital | Trial completion date: Feb 2025 --> Jun 2025

P2, N=6, Terminated, M.D. Anderson Cancer Center | Completed --> Terminated; Due to slow accrual

P4, N=86, Active, not recruiting, Emory University | Recruiting --> Active, not recruiting | N=60 --> 86 | Trial completion date: Mar 2026 --> Dec 2025 | Trial primary completion date: Mar 2026 --> Dec 2025

P1/2, N=80, Terminated, University of Queensland Centre for Clinical Research | Suspended --> Terminated

P1, N=40, Recruiting, Pfizer | Not yet recruiting --> Recruiting

Compared with the model group, low-, medium-, and high-dose Zhuyu Pills and atorvastatin calcium reduced the aortic plaque area, collagen deposition, liver lipid deposition, lipid droplets, and epididymal adipocyte volume, lowered the levels of iron ion and MDA and elevated the levels of SOD and GSH-Px in the serum, inhibited the expression of p53 and COX2, up-regulated the protein and mRNA levels of FTH1, SLC7A11, and GPX4, and down-regulated the mRNA levels of PTGS2 and NOX1 in the aorta. In conclusion, Zhuyu Pills exert definite therapeutic effect on aortic plaque in AS mice by regulating the p53/SLC7A11 signaling pathway to alleviate oxidative damage and inhibit ferroptosis.

Furthermore, our in vitro and in vivo studies demonstrated that treatment with statins, such as atorvastatin and simvastatin, induced ferroptosis and sensitized radioresistant HNSCC cells to irradiation, improving radiosensitivity and potentially enhancing the response to RT. Additionally, in xenograft models, the combination of statins and RT led to a significant reduction in tumor initiation. These findings provide valuable insights for enhancing treatment and improving prognosis in HPV-negative HNSCC by targeting ferroptosis and utilizing statins to sensitize tumors to RT-induced cell death.

P=N/A, N=522, Not yet recruiting, Tianjin Medical University General Hospital; Tianjin Medical University General Hospital

P1, N=228, Not yet recruiting, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine; Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

P1, N=30, Not yet recruiting, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

High-intensity rosuvastatin was superior to high-intensity atorvastatin in reducing the inflammatory response and myocardial fibrosis, thus improving ventricular remodeling and cardiac function better in STEMI patients.

P2, N=70, Recruiting, Northwestern University | Trial completion date: Dec 2024 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Sep 2025

Atorvastatin reduces the detrimental effects of cyclophosphamide in the POI model significantly by reducing oxidative stress and pro-inflammatory cytokines; regulating the expression of Bax, Bcl-2 and VEGF-A; and improving ovarian function and follicular reserve.

P=N/A, N=300, Completed, Lithuanian University of Health Sciences | Recruiting --> Completed

P2/3, N=220, Recruiting, University of Cape Town | Trial completion date: Jun 2026 --> Sep 2027 | Trial primary completion date: Jun 2024 --> Sep 2025

P1, N=40, Not yet recruiting, Pfizer

P1/2, N=60, Not yet recruiting, Minia University

P=N/A, N=129, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University

P4, N=137, Active, not recruiting, Organon and Co | Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Oct 2024

P4, N=60, Completed, Imperial College London | Unknown status --> Completed

Cedirogant (375 mg once daily) increased rosuvastatin maximum plasma concentration (Cmax) and area under the plasma concentration curve (AUCtau) by 141% and 55%, respectively when co-administered, whereas atorvastatin Cmax increased by 40% with no effect on its AUCtau compared with administration of rosuvastatin/atorvastatin alone. Correlation analysis with data from two investigational drugs (glecaprevir and flubentylosin) demonstrated that OATP1B1 R-value of > 1.5 and [Cmax,u]/[OATP1B1 IC50] of > 0.1 are associated with > 1.25-fold increase in CP-I Cmax ratio. This demonstrates the utility of CP-I in disentangling mechanisms underlying a complex DDI involving multiple transporters and enzymes and proposes refined criteria for static OATP1B inhibition predictions.

The results of the present study indicated that the anti-inflammatory, antioxidant, and neuroprotective properties of vitamin C and atorvastatin improved the effects of CCI in an empirical neuropathic in rats. Moreover, it was shown that the associated treatment with vitamin C and atorvastatin can reduce inflammatory factors, such as TNF-α and IL-6, and oxidative markers, such as glutathione peroxidase (GPx), superoxide dismutase (SOD), and malonaldehyde (MDA), while the nerve conduction velocity enhanced and inflammation decreased in histology studies in CCI rats.

P4, N=318, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

P1, N=48, Completed, Eccogene | Recruiting --> Completed

P2, N=672, Enrolling by invitation, University of California, San Francisco | Not yet recruiting --> Enrolling by invitation

P1, N=10, Completed, Zenith Technology Corp Ltd | Not yet recruiting --> Completed